Associate Professor, Department of Leukemia, MD Anderson Cancer Center - Research interest: phase I/II clinical trials in AML and ALL, developing new MRD assays
Houston, TX
Joined February 2017
- Tweets351
- Following180
- Followers2.2K
- Likes661
Nicholas Short MD retweeted
My commentary on the LTFU data from Short et al in Blood Advances with the addition of Gilteritinib to Azacitidine and Venetoclax for FLT3 mutant AML. Encouraging OS(29.7m) but myelosuppression in older adult(71 YO median) population remains a challenge. ashpublications.org/bloodadv…
Nicholas Short MD retweeted
Out in @tandfonline Expert Review of Hematology: our review on treatment of older adults with FLT3 mut AML, with focus on practical considerations of using HMA+VEN+FLT3i triplets.
tandfonline.com/eprint/HQG8E…
@Daver_Leukemia @NicholasShortMD @huntsmancancer @UTMDAnderson
#leusm
Nicholas Short MD retweeted
Excited and proud to share our special issue on #Leukemia that @ljmedeirosMD & I put together for @Human_Pathology We brought together incredible experts to write about the latest in the field.
13 articles, each one #hemepath GOLD💎! 1/14🧵
Starting with our intro to the issue sciencedirect.com/science/ar…
Nicholas Short MD retweeted
Grateful to receive an ASCO Young Investigator Award for our work investigating mechanisms of resistance and response to momelotinib plus gilteritinib in FLT3-mutated AML.
Thank you to my mentors @HusseinAbbasLab and @NicholasShortMD for their guidance and support #ASCO2026
Nicholas Short MD retweeted
Our new review explores how the definition of high-risk Ph+ ALL is shifting across tx eras.
Risk is dynamic, shaped by the interplay of biology, response, and treatment context. We examine key determinants, their evolving relevance, and risk-adapted strategies in the current era.
Nicholas Short MD retweeted
Kudos @Daver_Leukemia and @NicholasShortMD on not just your beautiful work but your outstanding mentorship of Dr. Azevedo! Outstanding long term follow up for aza ven gilt for adults w FLT3m AML inappropriate IC. #ASH25 #ASHScavengerHunt
Nicholas Short MD retweeted
Check out our most recent publication in @BloodCancerJnl evaluating the prognostic impact of early NGS-based MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL.
nature.com/articles/s41408-0…
@NicholasShortMD @DrHKantarjian
#Leusm #ALLsm
Nicholas Short MD retweeted
🚨 long-term outcomes in FLT3-m AML w/frontline HMA+VEN+FLT3 i
🔴93% CR/CRi in ND FLT3-m AML.
🔴3-yr OS: 45% (FLT3-ITD), 76% (FLT3-TKD)
🔴RASp mutations ➡️ poor survival
🔴ITD NGS MRD highly prognostic
🔴FLT3 wild-type relapses common. #Leusm #hemepath
haematologica.org/article/vi…
Nicholas Short MD retweeted
WBC >70K (but not IKZF1plus) increases risk of relapse with blina+ponatinib in Ph+ ALL, particularly extramedullary/CNS. Pts with high WBC should be considered for systemic MTX/Ara-C and/or CAR T-cell consolidation
jhoonline.biomedcentral.com/…
#leusm #ALL
Nicholas Short MD retweeted
Measurable residual disease is a powerful predictor of clinical outcomes in acute lymphoblastic leukemia. ow.ly/Y2iM50VonWG #MRD #ALL #lymphoidneoplasia
Nicholas Short MD retweeted
Expert recommendations on using MRD in #ALL now out in @BloodAdvances. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT
@MDAndersonNews #Leukemia
doi.org/10.1182/bloodadvance…
#leusm
Nicholas Short MD retweeted
Recommendations from a panel of US experts published in @BloodAdvances highlight the optimal use of MRD as a prognostic and therapeutic tool in adult ALL
More news: loom.ly/EvtL7yw
#ALLsm #leusm #MedNews #MedEd
Nicholas Short MD retweeted
Early attainment of undetectable MRD by MFC is independently associated w/ improved RFS in newly diagnosed #AML. Intermediate risk pts who attain undetectable MRD should still undergo consolidative allo-SCT.
@MDAndersonNews #Leukemia
@ASH_hematology
ashpublications.org/bloodadv…
Very nice of @AjHematology to add a wonderful visual abstract to accompany our review article on MRD in AML. Link here: onlinelibrary.wiley.com/doi/…
@DillonHaem
MRD is highly prognostic in #AML and can inform SCT decisions or enrollment into MRD-directed clinical trials. MRD endpoints may also allow for accelerated drug approval in AML. New review by @NicholasShortMD and Richard Dillon in @AjHematology
doi.org/10.1002/ajh.27482
#leusm
Nicholas Short MD retweeted
CONGRESS #ASH24 | PRESENTATION
@WNMacaron, @MDAndersonNews and @bcmhouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1. Poorer outcomes occurred in pts with HR B-ALL and slow MRD response. Follow our live feed for more updates: lymphoblastic-hub.com/medica…
#ALL #ALLsm
Nicholas Short MD retweeted
CONGRESS #ASH24 | PRESENTATION
Roberta Santos Azevedo, @MDAndersonNews discussed older age and TP53 mutations as predictors of myeloid neoplasm. Incidence of t-MN was highest in pts older than 60, and also higher with treatment intensity and TP53 mutation. t-MN risk was highest in pts over 60 with TP53 mutation, with a 5-yr CI of 25% Follow our live feed for more updates: lymphoblastic-hub.com/medica…
#ALL #ALLsm
Nicholas Short MD retweeted
CONGRESS | #ASH24 | PRESENTATION
@NicholasShortMD @MDAndersonNews shares long-term findings from a study of patients with ND FLT3m AML treated with HMA+Ven+FLT3i triplet (N = 73).
▪️Efficacy overall was comparable to that seen with doublet therapy, and at median follow-up of 26 months, median RFS=28.8 months and median OS = 38.5 months.
▪️Differences were seen between patients FT3-ITD (mOS=28.1 months) and FLT3-TKD (mOS=39.3 months).
▪️Age, NPM1, ELN 2022 risk, or allo-HSCT did not impact survival.
▪️In the 17 patients who relapsed with available sequencing information, 65% were FLT3 negative at relapse; 12 patients had clonal evolution, with new RAS pathway mutations identified in 24%.
▪️Poor responses were observed with triplet therapy post-relapse, particularly in patients with FLT3 mutation at relapse (median OS = 1.6 months).
Follow our live feed for more updates: aml-hub.com/medical-informat…
#AMLsm #leusm
Nicholas Short MD retweeted
Save the Date! @calliecoombsmd @JohnPLeonardMD @Ramikomrokji @farrukhawan @NicholasShortMD @szusmani @DrKrinaPatel @corinneShahmehdi @jmaakaron @CLachowiez
Register at louisville.edu/medicine/cme/…
@UofLBCC @UofLHealth @UofLMedicine @uoflmedschool @uofl
Nicholas Short MD retweeted
MRD is highly prognostic in #AML and can inform SCT decisions or enrollment into MRD-directed clinical trials. MRD endpoints may also allow for accelerated drug approval in AML. New review by @NicholasShortMD and Richard Dillon in @AjHematology
doi.org/10.1002/ajh.27482
#leusm
Happy to see our trial of DAC, venetoclax and ponatinib for advanced phase CML published in @TheLancetHaem. Response rate was 80%, allowing for bridge to alloSCT. Still a lot more work to be done in this rare disease. We have new TKI combo studies now open and enrolling.
In a Phase II trial led by Dr. Nicholas Short, 80% of patients with previously untreated chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia achieved remission with a novel treatment combination: bit.ly/4eaCHh0 @NicholasShortMD #EndCancer